{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:19:28Z","timestamp":1773515968329,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI135537-01"],"award-info":[{"award-number":["R21 AI135537-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000128"],"award-info":[{"award-number":["UL1 TR000128"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007804","name":"Oregon Clinical and Translational Research Institute","doi-asserted-by":"publisher","award":["IISR 2016\u2013101586"],"award-info":[{"award-number":["IISR 2016\u2013101586"]}],"id":[{"id":"10.13039\/100007804","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sunlin and Priscilla Chou Foundation"},{"DOI":"10.13039\/100008143","name":"Oregon National Primate Research Center","doi-asserted-by":"publisher","award":["8P51 OD011092"],"award-info":[{"award-number":["8P51 OD011092"]}],"id":[{"id":"10.13039\/100008143","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The once-in-a-lifetime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scrutiny of the durability of immunity after 17D vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a cross-sectional analysis of 17D vaccinees living in nonendemic Portland, Oregon. Neutralization assays were used to determine YFV immunity. The relationships between 17D immunity and vaccination history, demographics, and travel were evaluated using nominal logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutralization test \u22651:10) at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at \u226510 years after single-dose vaccination. No relationship was found between YFV immunity and time in endemic countries, other flavivirus immunity, or demographics. Subjects were most likely to become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.12\u20132.73). A comparison of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI, 70%\u201386%) of vaccinees are likely to be seropositive \u226510 years postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at ~10 years postvaccination, and a booster vaccination should be considered for nonendemic vaccinees before travel to regions where there is a high risk of YFV transmission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz374","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T19:10:04Z","timestamp":1565896204000},"page":"2018-2025","source":"Crossref","is-referenced-by-count":26,"title":["Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting"],"prefix":"10.1093","volume":"221","author":[{"given":"Bettie W","family":"Kareko","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L","family":"Booty","sequence":"first","affiliation":[{"name":"Oregon Clinical and Translational Research Institute, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad D","family":"Nix","sequence":"first","affiliation":[{"name":"Department of Infection Prevention and Control, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe L","family":"Lyski","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Portland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K","family":"Slifka","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Portland"},{"name":"Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian J","family":"Amanna","sequence":"first","affiliation":[{"name":"Najit Technologies, Inc., Beaverton, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B","family":"Messer","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Portland"},{"name":"Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University,, Portland"},{"name":"OHSU-PSU School of Public Health, Oregon Health and Science University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"2020061115544057200_CIT0001","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S1473-3099(16)30518-7","article-title":"Epidemic arboviral diseases: priorities for research and public health","volume":"17","author":"Wilder-Smith","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020061115544057200_CIT0002","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2020061115544057200_CIT0003","doi-asserted-by":"crossref","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med"},{"key":"2020061115544057200_CIT0004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(16)30513-8","article-title":"Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study","volume":"17","author":"Kraemer","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020061115544057200_CIT0005","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41598-017-05186-3","article-title":"Potential risk of re-emergence of urban transmission of Yellow Fever virus in Brazil facilitated by competent Aedes populations","volume":"7","author":"Couto-Lima","year":"2017","journal-title":"Sci Rep"},{"key":"2020061115544057200_CIT0006","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1473-3099(16)30588-6","article-title":"Responding to the threat of urban yellow fever outbreaks","volume":"17","author":"Wilder-Smith","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020061115544057200_CIT0007","author":"Boadle"},{"key":"2020061115544057200_CIT0008","article-title":"Yellow fever patient in Republic of Congo prompts outbreak declaration, response","volume-title":"Science Speaks; Global ID News","author":"Barton","year":"2018"},{"key":"2020061115544057200_CIT0009","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax008","article-title":"Importation of yellow fever into China: assessing","volume":"24","author":"Wilder-Smith","year":"2017","journal-title":"J Travel Med"},{"key":"2020061115544057200_CIT0010","first-page":"1","article-title":"Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002","volume":"51","author":"Cetron","year":"2002","journal-title":"MMWR Recomm Rep"},{"key":"2020061115544057200_CIT0011","volume-title":"Vaccines","author":"Monath","year":"2013","edition":"6"},{"key":"2020061115544057200_CIT0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"2020061115544057200_CIT0013","author":"Centers for Disease Control and Prevention"},{"key":"2020061115544057200_CIT0014","first-page":"345","article-title":"Yellow fever vaccine: WHO position on the use of fractional doses - June 2017","volume":"92","year":"2017","journal-title":"Releve Epidemiologique Hebdomadaire"},{"key":"2020061115544057200_CIT0015","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1016\/j.vaccine.2017.06.087","article-title":"WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: position paper - June 2013","volume":"35","author":"World Health Organization","year":"2017","journal-title":"Vaccine"},{"key":"2020061115544057200_CIT0016","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report.","volume":"381","author":"Casey","year":"2019","journal-title":"N Engl J Med"},{"key":"2020061115544057200_CIT0017","first-page":"269","article-title":"Vaccines and vaccination against yellow fever: WHO position paper--June 2013","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"2020061115544057200_CIT0018","first-page":"647","article-title":"Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020061115544057200_CIT0019","author":"World Health Organization"},{"key":"2020061115544057200_CIT0020","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","article-title":"Duration of post-vaccination immunity against yellow fever in adults","volume":"32","author":"Collaborative Group for Studies on Yellow Fever Vaccines","year":"2014","journal-title":"Vaccine"},{"key":"2020061115544057200_CIT0021","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1590\/0037-8682-0007-2012","article-title":"Serologic assessment of yellow fever immunity in the rural population of a yellow fever-endemic area in Central Brazil","volume":"46","author":"Machado","year":"2013","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020061115544057200_CIT0022","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4269\/ajtmh.2011.10-0496","article-title":"Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil","volume":"85","author":"de Melo","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020061115544057200_CIT0023","first-page":"796","article-title":"[Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue]","volume":"10","author":"G\u00f3mez","year":"2008","journal-title":"Rev Salud Publica"},{"key":"2020061115544057200_CIT0024","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s13149-011-0135-7","article-title":"[Long term persistence of yellow fever neutralising antibodies in elderly persons]","volume":"104","author":"Coulange Bodilis","year":"2011","journal-title":"Bull Soc Pathol Exot"},{"key":"2020061115544057200_CIT0025","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop Med Int Health"},{"key":"2020061115544057200_CIT0026","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J Med Virol"},{"key":"2020061115544057200_CIT0027","first-page":"895","article-title":"Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ"},{"key":"2020061115544057200_CIT0028","author":"Centers for Disease Control and Prevention"},{"key":"2020061115544057200_CIT0029","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop Med Int Health"},{"key":"2020061115544057200_CIT0030","article-title":"Persistence","author":"Lindsey","year":"2018","journal-title":"J Travel Med"},{"key":"2020061115544057200_CIT0031","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","article-title":"Booster dose after 10 years is recommended following 17DD-YF primary vaccination","volume":"12","author":"Campi-Azevedo","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2020061115544057200_CIT0032","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1016\/j.vaccine.2018.05.041","article-title":"Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study","volume":"36","author":"de Menezes Martins","year":"2018","journal-title":"Vaccine"},{"key":"2020061115544057200_CIT0033","article-title":"Collaborative group","author":"Camacho","year":"2019","journal-title":"Vaccine"},{"key":"2020061115544057200_CIT0034","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/M18-1529","article-title":"Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial","volume":"169","author":"Roukens","year":"2018","journal-title":"Ann Intern Med"},{"key":"2020061115544057200_CIT0035","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/S0140-6736(16)31838-4","article-title":"Fractional dosing of yellow fever vaccine to extend supply: a modelling study","volume":"388","author":"Wu","year":"2016","journal-title":"Lancet"},{"key":"2020061115544057200_CIT0036","author":"PAHO"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/12\/2018\/33379774\/jiz374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/12\/2018\/33379774\/jiz374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:09:35Z","timestamp":1591909775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/12\/2018\/5572834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,9,23]]},"published-print":{"date-parts":[[2020,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz374","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,15]]},"published":{"date-parts":[[2019,9,23]]}}}